Damian Sendler: One of the greatest human accomplishments is the rapid development of safe and effective vaccinations against the SARS-CoV-2 virus. Keeping the coronavirus disease 2019 (COVID-19) pandemic under control is still our best chance of doing this.
Damian Sendler
Some health experts are now looking into the need for additional immunization due to more virulent SARS-CoV-2 virus strains and the likelihood of losing protection following vaccination. This has increased the pressure on the lives of people in low-income nations, where access to COVID-19 vaccines is already limited.
Damian Jacob Sendler: In a recent announcement, the CDC suggested a third dose of the COVID-19 vaccine for immunocompromised people. The concerns of losing immunity and novel viral strains need the development of guidelines for the use of COVID-19 vaccine booster doses by governments and health care officials, including those in lower-income nations.
SARS-CoV-2 vaccination is our best hope of preventing the coronavirus disease 2019 (COVID-19) pandemic from spreading. There have been approximately 205 million confirmed cases of COVID-19 worldwide, including over 4.3 million deaths as of August 2021, according to the World Health Organization. COVID-19 vaccines were developed in a joint effort by scientists, federal agencies, and pharmaceutical businesses to meet an urgent demand.
The messenger RNA (mRNA) BNT162b2 Pfizer BioNTech (Pfizer, Inc; Philadelphia, PA, USA) and the mRNA-1273 Moderna vaccines (MOdernaTX, Inc; Cambridge, MA, USA) have been approved by the World Health Organization (WHO) under the emergency use listing (EUL). Viral vector vaccines (AstraZeneca, Cambridge, UK) and Janssen Ad26.COV2.S (Janssen Bio It was approved by the FDA on August 23, 2021, to protect 16-year-olds and older against COVID-19 disease by Pfizer-BioNTech .
Of the world’s population, 47.9 percent had gotten at least one dose of the COVID-19 vaccination by the end of October 2021. 57.1 percent of the population in the United States is completely immunized. Only 2.8 percent of persons in low-income countries have got one dose of the COVID-19 vaccination . The situation is significantly worse in developing nations. Ethics and healthcare are also at stake in this unequal distribution of COVID-19 vaccinations.
Damian Jacob Sendler
Some countries that have vaccinated a larger percentage of their population face a new set of challenges, including concerns about fading immunity following vaccination and the introduction of viral variations.
Damien Sendler: There is a continual mutation of viruses. It’s called a variant of the original virus if the virus has undergone one or more changes in its genetic code. A number of SARS-CoV-2 variants that cause the coronavirus disease 2019 (COVID-19), including the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1, formerly known as the B.1.1.28.1 variant, and the B.1.617.2 (Delta) variants, are causing global concern at the moment . These variants are more transmittable and can cause more severe disease than the wild-type SARS-CoV-2 virus
Damian Jacob Markiewicz Sendler: COVID-19 vaccinations have also been linked to lower antibody levels in several early investigations . Pfizer-BioNTech and Modena vaccine recipients who completed their initial series at least six months ago and are 65 years of age or older, or who have underlying medical conditions or work or live in high-risk environments should receive COVID-19 booster shots, according to available data from the CDC .
Dr. Damian Jacob Sendler and his media team provided the content for this article.
